BRR2 Antibody

What is BRR2 and why are antibodies against it important for splicing research?

BRR2 (also known as SNRNP200) is an essential RNA helicase that belongs to the Ski2-like subfamily and functions as a critical component of the spliceosome. It catalyzes ATP-dependent unwinding of the U4/U6 RNA duplex, which is a necessary step for spliceosomal activation . The human version of BRR2 has a canonical amino acid length of 2136 residues and a protein mass of 244.5 kilodaltons with two identified isoforms .

Antibodies against BRR2 are crucial for investigating splicing mechanisms because they allow researchers to:

• Track BRR2 localization within nuclear compartments

• Isolate BRR2-containing splicing complexes through immunoprecipitation

• Examine BRR2 expression levels in different tissue types

• Study modifications that regulate BRR2 helicase activity

Since BRR2 is widely expressed in many tissue types and primarily localized in the nucleus , antibodies provide a valuable tool for understanding its role in fundamental cellular processes and disease states.

What experimental applications are most suitable for BRR2 antibodies?

BRR2 antibodies have demonstrated utility in multiple experimental techniques:

For optimal results, researchers should select BRR2 antibodies validated specifically for their application of interest. Several commercial antibodies have been validated for Western blotting and immunoprecipitation , making these the most reliable applications. When studying BRR2 in experimental settings, it's essential to consider its association with large, salt-stable snRNP complexes containing U1, U2, U4, U5, and U6 snRNPs .

How should I select the appropriate BRR2 antibody for my experimental system?

Selection of an appropriate BRR2 antibody depends on several key factors:

• Species reactivity: Available BRR2 antibodies demonstrate reactivity with different species including human, mouse, Saccharomyces, Schizosaccharomyces, and bacteria . Ensure the antibody recognizes BRR2 from your experimental model.

• Antibody type: Both polyclonal and monoclonal antibodies are available. Polyclonal antibodies may provide higher sensitivity but potentially lower specificity than monoclonals.

• Epitope location: Consider whether your research requires an antibody targeting the N-terminal or C-terminal cassette of BRR2, particularly if studying specific domains involved in helicase activity or protein interactions.

• Validation data: Request supporting validation data showing the antibody's performance in applications similar to your intended use. Look for evidence of specificity such as knockdown controls or recombinant protein testing.

• Alternative names: When searching for antibodies, remember that BRR2 is also known as SNRNP200, ASCC3L1, and HELIC2 . Searching under these alternative names may yield additional antibody options.

For studies investigating BRR2 mutations associated with retinitis pigmentosa, select antibodies that can effectively detect both wild-type and mutant forms of the protein .

How can BRR2 antibodies be utilized to study spliceosome assembly and dynamics?

BRR2 antibodies offer powerful tools for investigating spliceosome assembly and remodeling:

Immunoprecipitation-based spliceosome isolation:
BRR2 exists in large complexes containing U1, U2, U5, and U4/U6 snRNPs even in the absence of pre-mRNA . Researchers can leverage this property by using BRR2 antibodies to immunoprecipitate intact spliceosomal complexes. Studies have demonstrated that BRR2 complexes immunopurified with polyoma-tagged antibodies can be used to monitor ATP-dependent disruption of U4/U6 base-pairing .

Methodology for studying BRR2-mediated unwinding:

• Immunopurify BRR2-containing complexes using antibodies against epitope-tagged BRR2

• Incubate the isolated complexes with or without ATP

• Separate the beads from the supernatant

• Analyze the RNA content through northern blotting

• Use non-denaturing gels to distinguish between duplex U4/U6 and free snRNAs

This approach has revealed that wild-type BRR2 complexes release free U4 and U6 snRNAs in response to ATP, while mutant BRR2-1 complexes fail to disrupt the U4/U6 duplex .

Kinetic analysis:
Time-course experiments using BRR2 antibodies can track the progression of spliceosome assembly and activation by isolating complexes at different stages. This allows researchers to monitor the temporal dynamics of BRR2-associated factors during splicing.

What insights can BRR2 antibodies provide in retinitis pigmentosa research?

BRR2 (SNRNP200) mutations are linked to autosomal dominant retinitis pigmentosa (RP), a degenerative eye disease . BRR2 antibodies offer several methodological approaches for investigating this connection:

Comparative expression analysis:
By using BRR2 antibodies in Western blots of retinal tissues, researchers can compare expression levels between normal and RP-affected samples. This can reveal whether certain mutations affect protein stability or expression.

Functional analysis of mutant BRR2 proteins:

• Generate cell lines expressing wild-type or RP-associated mutant BRR2

• Immunoprecipitate the BRR2 complexes using specific antibodies

• Compare the composition of associated factors and snRNPs

• Assess helicase activity through unwinding assays

• Evaluate ATP hydrolysis efficiency

Studies utilizing such approaches have shown that mutations linked to RP negatively impact spliceosome activation, likely due to defects in the RNA binding, helicase, and ATPase activities of mutant BRR2 .

Tissue-specific effects:
BRR2 antibodies can help investigate why mutations in this ubiquitously expressed splicing factor predominantly affect retinal tissues. Immunohistochemistry with BRR2 antibodies in different tissues can reveal potential differences in expression patterns or localization.

How can BRR2 antibodies be used to study inhibitors targeting the spliceosomal machinery?

Recent research has identified small molecule inhibitors of BRR2, highlighting potential therapeutic and research applications . BRR2 antibodies provide critical tools for studying these inhibitors:

Characterizing inhibitor binding sites:
High-throughput screening has identified two different classes of BRR2 inhibitors that bind to distinct sites:

• Compound 3: Binds to an allosteric site between the C-terminal and N-terminal helicase cassettes

• Compound 12: Binds to an RNA-binding site inside the N-terminal cassette

Researchers can use BRR2 antibodies in competitive binding assays to verify inhibitor interactions and identify additional binding partners.

Evaluating inhibitor effects on BRR2 interactions:

• Treat cells or cell extracts with BRR2 inhibitors

• Immunoprecipitate BRR2 complexes using specific antibodies

• Analyze changes in co-precipitating proteins and RNAs

• Compare results with control samples to identify disrupted interactions

Developing assays for inhibitor screening:
BRR2 antibodies can facilitate the development of high-throughput assays for identifying more potent and selective inhibitors. For example, researchers have used BRR2 inhibitor 9, which shows potent and selective helicase inhibitory activity , as a starting point for molecular probe development.

What controls should be included when using BRR2 antibodies in immunoblotting and immunoprecipitation?

Essential controls for BRR2 antibody experiments:

Specific considerations for BRR2:
When working with BRR2 antibodies, include controls that account for its unique characteristics:

• Size verification: BRR2 is a large protein (~244.5 kDa) , so include molecular weight markers that extend to this range.

• Specificity validation: In immunoprecipitation experiments, verify specificity by showing that peptide encoding the targeted epitope competes for immunoprecipitation of BRR2-associated snRNAs .

• ATP controls: For functional studies, include both ATP and non-hydrolyzable ATP analogs to distinguish between ATP binding and hydrolysis requirements.

• Fractionation controls: Since BRR2 is nuclear-localized , include proper nuclear extraction controls and nuclear envelope markers.

What are the optimal protocols for immunoprecipitating BRR2-containing spliceosomal complexes?

Optimized protocol for BRR2 immunoprecipitation:

• Cell lysis and extract preparation:

  • Use gentle lysis buffers (typically containing 50-150 mM NaCl, 0.1% NP-40, 50 mM Tris-HCl pH 7.5)

  • Include protease inhibitors, phosphatase inhibitors, and RNase inhibitors

  • Perform all steps at 4°C to preserve complex integrity

• Pre-clearing and antibody binding:

  • Pre-clear extract with protein G-Sepharose alone to remove non-specific binding

  • Incubate extract with BRR2 antibody (2-5 μg per mg of protein)

  • For tagged BRR2, anti-tag antibodies (e.g., anti-polyoma) coupled to protein G-Sepharose have proven effective

• Washing conditions:

  • BRR2 associations with snRNPs are salt-resistant up to 350 mM NaCl

  • Use a stepwise washing series (e.g., 50 mM, 150 mM, 250 mM, 350 mM NaCl) to determine optimal stringency

  • Include controls at each salt concentration to monitor specificity

• Elution methods:

  • For protein analysis: SDS elution buffer heated to 95°C

  • For functional studies: Gentle elution with excess epitope peptide

  • For RNA analysis: Direct extraction from beads using phenol-chloroform

• Analysis of immunoprecipitated complexes:

  • For RNA detection: Northern blotting with probes for U1, U2, U4, U5, and U6 snRNAs

  • For protein detection: Western blotting with antibodies against spliceosomal proteins

  • For functional assays: Incubate immunoprecipitates with ATP and analyze unwinding activity

How should researchers optimize Western blot protocols for detecting BRR2?

Optimized Western blot protocol for BRR2 detection:

• Sample preparation:

  • Nuclear extraction is crucial since BRR2 is primarily nuclear-localized

  • Use specialized buffers for large nuclear proteins (e.g., RIPA with 0.5% deoxycholate)

  • Include protease inhibitors to prevent degradation of this large protein

• Gel electrophoresis considerations:

  • Use low percentage gels (6-8%) or gradient gels (4-15%) to effectively resolve the 244.5 kDa BRR2 protein

  • Run gels at lower voltage (80-100V) for longer periods to improve resolution

  • Include high molecular weight markers

• Transfer optimization:

  • Use wet transfer methods rather than semi-dry for large proteins

  • Extend transfer time (overnight at 30V, 4°C) or use specialized systems for large proteins

  • Add 0.05-0.1% SDS to transfer buffer to facilitate movement of large proteins

• Antibody incubation:

  • Longer primary antibody incubation (overnight at 4°C) with gentle agitation

  • Optimize antibody dilution (typically starting at 1:500-1:1000)

  • Extended washing steps (6×10 minutes) to reduce background

• Detection considerations:

  • Use higher sensitivity detection methods (ECL-Plus or fluorescent secondary antibodies)

  • Longer exposure times may be necessary due to the size of the protein

  • Consider stain-free technology to verify transfer of high molecular weight proteins

How can researchers troubleshoot specificity issues with BRR2 antibodies?

When encountering specificity issues with BRR2 antibodies, systematically address potential problems:

Multiple bands in Western blot:

• Verify BRR2 isoforms - Human BRR2 has two identified isoforms

• Check for degradation - Use fresher samples and additional protease inhibitors

• Evaluate antibody cross-reactivity - Test the antibody against recombinant BRR2 fragments

• Optimize blocking conditions - Try different blocking agents (BSA vs. milk)

• Perform siRNA knockdown - Confirm which bands decrease with BRR2 depletion

Weak or no signal:

• Ensure extraction efficiency - BRR2 is nuclear and may require specialized extraction

• Verify sample integrity - Confirm protein quality through Ponceau staining

• Test alternative epitopes - Different antibodies may target different regions of BRR2

• Adjust antibody concentration - Titrate to determine optimal working concentration

• Enhance detection methods - Use amplification systems for weak signals

Background in immunoprecipitation:

• Increase pre-clearing steps - Remove non-specific binding proteins

• Test different antibody amounts - Optimize antibody-to-sample ratio

• Modify wash stringency - Adjust salt concentration (keeping in mind BRR2 complexes are stable up to 350 mM NaCl)

• Use alternative beads - Compare protein A, protein G, or combo beads

• Include competing peptides - Assess specificity through peptide competition

How should researchers interpret BRR2 expression data in the context of splicing efficiency?

Correlating BRR2 expression with splicing activity requires careful data interpretation:

Quantitative analysis approach:

• Normalize BRR2 levels to appropriate housekeeping controls

• Compare BRR2 expression with other spliceosomal components (e.g., U5 snRNP proteins)

• Correlate expression with splicing reporters or endogenous splicing events

• Consider post-translational modifications that may affect BRR2 activity

Interpreting mutations and variants:
Mutations in BRR2, particularly those associated with retinitis pigmentosa, can affect splicing fidelity even when expression levels appear normal . Researchers should:

• Compare helicase activity between wild-type and mutant BRR2

• Assess ATP hydrolysis efficiency using biochemical assays

• Evaluate U4/U6 unwinding in native snRNP complexes

• Examine spliceosome assembly and activation kinetics

Tissue-specific considerations:
Despite being widely expressed , BRR2 dysfunction may affect tissues differently. When interpreting BRR2 expression data:

• Consider tissue-specific splicing requirements

• Evaluate expression of BRR2 regulators in the tissue

• Assess alternative splicing patterns characteristic of the tissue

• Compare nuclear distribution patterns across tissues

What methodological approaches can address contradictory results in BRR2 antibody experiments?

When faced with contradictory results using BRR2 antibodies, consider these methodological approaches:

Antibody validation matrix:
Create a comprehensive validation using multiple techniques:

Reconciling discrepancies:

• Epitope accessibility issues: Different antibodies may detect distinct conformational states of BRR2. Test multiple antibodies targeting different regions.

• Complex formation effects: BRR2 exists in large snRNP complexes which may mask certain epitopes. Compare results using different extraction and denaturation conditions.

• Experimental condition variations: Systematically document all variables between contradictory experiments, including buffer compositions, incubation times, and detection methods.

• Cross-reactivity with homologs: Confirm specificity against other DExD/H-box RNA helicases. Use mass spectrometry to identify all proteins recognized by the antibody.

• Functional validation: Move beyond simple detection to activity assays. For instance, immunoprecipitated BRR2 should disrupt U4/U6 base-pairing in the presence of ATP, while mutant BRR2-1 fails to do so .

How might BRR2 antibodies facilitate research into novel splicing mechanisms?

BRR2 antibodies offer promising approaches for investigating emerging areas of splicing research:

Exploring BRR2 as a splicing fidelity factor:
Recent research identifies BRR2 as a fidelity factor during pre-mRNA splicing . Antibodies can help elucidate how BRR2 promotes on-pathway interactions while minimizing errors by:

• Immunoprecipitating BRR2 complexes at different splicing stages

• Comparing co-precipitating factors between normal and error-prone conditions

• Detecting conformational changes using conformation-specific antibodies

Investigating allosteric regulation:
The discovery of allosteric inhibitors targeting BRR2 suggests complex regulatory mechanisms. Researchers can use BRR2 antibodies to:

• Study protein interactions at the allosteric site between N-terminal and C-terminal cassettes

• Monitor conformational changes upon inhibitor binding

• Identify natural regulators that might act at these sites

Connecting BRR2 to specialized cellular processes:
Beyond constitutive splicing, BRR2 antibodies can help explore roles in:

• Stress-induced splicing changes

• Alternative splicing regulation

• RNA surveillance pathways

• Tissue-specific splicing programs

What technological advances might improve BRR2 antibody applications in spliceosome research?

Emerging technologies promise to enhance BRR2 antibody applications:

Single-molecule approaches:
Combining BRR2 antibodies with single-molecule techniques could reveal:

• Real-time unwinding kinetics of individual BRR2 molecules

• Heterogeneity in BRR2 complex composition

• Step-by-step spliceosome assembly mechanisms

Proximity labeling methods:
BioID or APEX2 fusions with BRR2 combined with antibody-based detection can:

• Map the dynamic BRR2 interactome during splicing

• Identify transient interaction partners

• Reveal spatial organization of BRR2 within nuclear speckles

Antibody engineering:
Development of specialized BRR2 antibodies could include:

• Activity-state specific antibodies that recognize ATP-bound vs. ADP-bound states

• Split antibody complementation systems to detect BRR2 conformational changes

• Intrabodies for tracking BRR2 dynamics in living cells

High-throughput screening applications:
BRR2 antibodies could facilitate development of:

• FRET-based sensors for BRR2 activity in vitro and in cells

• AlphaScreen or TR-FRET assays for drug discovery

• Microscopy-based screens for splicing modulators